Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

  • Filters activated: AIDS. Clear all to show 86 items.
  • Quoted phrase not found.
1.

Phenotypic, ultra-structural, and functional characterization of bovine peripheral blood dendritic cell subsets.

Sei JJ, Ochoa AS, Bishop E, Barlow JW, Golde WT.

PLoS One. 2014 Oct 8;9(10):e109273. doi: 10.1371/journal.pone.0109273. eCollection 2014.

2.

CpG7909 adjuvant enhanced immunogenicity efficacy in mice immunized with ESAT6-Ag85A fusion protein, but does not confer significant protection against Mycobacterium tuberculosis infection.

Hu S, Chen H, Ma J, Chen Q, Deng H, Gong F, Huang H, Shi C.

J Appl Microbiol. 2013 Nov;115(5):1203-11. doi: 10.1111/jam.12315. Epub 2013 Aug 27.

3.

Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.

Winckelmann AA, Munk-Petersen LV, Rasmussen TA, Melchjorsen J, Hjelholt TJ, Montefiori D, Østergaard L, Søgaard OS, Tolstrup M.

PLoS One. 2013 Apr 26;8(4):e62074. doi: 10.1371/journal.pone.0062074. Print 2013.

4.

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults.

Offersen R, Melchjorsen J, Paludan SR, Østergaard L, Tolstrup M, Søgaard OS.

Hum Vaccin Immunother. 2012 Aug;8(8):1042-7. doi: 10.4161/hv.20707. Epub 2012 Aug 1.

5.

Efficient in vivo priming by vaccination with recombinant NY-ESO-1 protein and CpG in antigen naive prostate cancer patients.

Karbach J, Neumann A, Atmaca A, Wahle C, Brand K, von Boehmer L, Knuth A, Bender A, Ritter G, Old LJ, Jäger E.

Clin Cancer Res. 2011 Feb 15;17(4):861-70. doi: 10.1158/1078-0432.CCR-10-1811. Epub 2010 Dec 16.

6.

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.

Kuball J, de Boer K, Wagner E, Wattad M, Antunes E, Weeratna RD, Vicari AP, Lotz C, van Dorp S, Hol S, Greenberg PD, Heit W, Davis HL, Theobald M.

Cancer Immunol Immunother. 2011 Feb;60(2):161-71. doi: 10.1007/s00262-010-0929-7. Epub 2010 Oct 21.

7.

Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy.

Søgaard OS, Schønheyder HC, Bukh AR, Harboe ZB, Rasmussen TA, Ostergaard L, Lohse N.

AIDS. 2010 Jun 1;24(9):1315-22. doi: 10.1097/QAD.0b013e328339fe0b.

PMID:
20559037
8.

CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years.

Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW.

Clin Infect Dis. 2008 Apr 15;46(8):1310-4. doi: 10.1086/533467.

PMID:
18444872
9.

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW.

AIDS. 2005 Sep 23;19(14):1473-9.

PMID:
16135900

Supplemental Content

Loading ...
Support Center